BioCentury | Nov 14, 2013
Targets & Mechanisms

RSVing for site zero

Despite decades of research, respiratory syncytial virus (RSV) remains a highly prevalent childhood pathogen without an approved vaccine. 1 There is a marketed prophylactic- Synagis palivizumab-to prevent severe disease caused by RSV in at-risk infants,...
BioCentury | Sep 10, 2012
Clinical News

ALN-RSV01: Final Phase II data

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Jun 4, 2012
Clinical News

ALN-RSV01: Phase IIb data

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Dec 5, 2011
Clinical News

ALN-RSV01: Completed Phase IIb enrollment

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Jul 5, 2010
Clinical News

ALN-RSV01: Final Phase II data

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Mar 1, 2010
Clinical News

ALN-RSV01: Phase IIb started

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Dec 17, 2009
Distillery Therapeutics

Indication: Infectious disease

...Infectious disease Respiratory syncytial virus (RSV) RSV nucleocapsid The crystal structure of a portion of the RSV nucleocapsid-RNA...
...N-terminal domain inserts. Next steps could include using the structure to guide the development of RSV nucleocapsid...
BioCentury | Jul 27, 2009
Clinical News

ALN-RSV01: Final Phase II data

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | Jun 22, 2009
Clinical News

ALN-RSV01: Phase II data

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
BioCentury | May 18, 2009
Clinical News

ALN-RSV01: Completed Phase II enrollment

...Mass. Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Product: ALN-RSV01 Business: Infectious Molecular target: RSV nucleocapsid...
Items per page:
1 - 10 of 10